4x4

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of 4x4

What is 4x4? Defining the Medicine

Property Description
Active ingredient Sildenafil (Sildenafil citrate)
Form Oral tablet, Oral suspension, IV solution
Pharmacological class Phosphodiesterase Type 5 (PDE5) Inhibitor
Common Use Optimizing blood flow for enhanced physiological responses
Origin Synthetic compound

The medication designated as 4x4 is a specific brand-name pharmaceutical product that uses the active ingredient Sildenafil, a substance belonging to the drug class known as Phosphodiesterase Type 5 (PDE5) Inhibitors. Sildenafil is a synthetic compound manufactured as a single-ingredient product, and the brand is typically categorized as prescription-only (Rx). This classification is significant as it fundamentally indicates the drug's core mechanism and general benefit.

The general purpose of this medicine is to promote selective smooth-muscle relaxation and enhance local blood flow in certain areas of the body. Sildenafil achieves this by acting as a selective inhibitor of the PDE5 enzyme, which naturally regulates the degradation of a chemical messenger called cGMP. Inhibiting this enzyme helps sustain the signals for vasodilation, a mechanism that is clinically recognized for its efficacy in improving circulatory dynamics. The resulting increase in local circulation forms the basis for the drug's intended therapeutic benefits.


4x4: Form, Composition, and General Purpose

The most prevalent dosage form for 4x4 is the oral tablet, typically film-coated, designed for convenient ingestion via the oral route of administration. The basic composition includes the active substance, Sildenafil citrate, and pharmaceutical excipients required for stability and structure. Sildenafil is also manufactured as an oral suspension and a solution for intravenous injection for use in specialized clinical environments. The primary feature of the product 4x4 is its brand positioning, though its core formulation remains consistent with other Sildenafil products, sharing the same key pharmacological class and mechanism of action.

Regulatory References

  1. Sildenafil: MedlinePlus Drug Information
  2. Sildenafil ratiopharm | European Medicines Agency (EMA)
  3. SILDENAFIL tablet - DailyMed - NIH

What side effects are possible with 4x4?

Possible Side Effects and Safety Information

The safety profile of 4x4 is documented in regulatory labeling and includes adverse reactions observed during clinical trials and post-marketing surveillance.

Adverse Reactions by Frequency and System

Adverse reactions are classified according to frequency using established regulatory frameworks (e.g., ICH guidelines) and are presented by System Organ Class (SOC). Key categories of adverse drug reactions (ADRs) are documented as follows:

Classification Example System Organ Class (SOC)
Very Common (ge 1/10) Gastrointestinal Disorders (e.g., nausea)
Common (ge 1/100 to < 1/10) Nervous System Disorders (e.g., headache), Skin and Subcutaneous Tissue Disorders (e.g., rash)
Uncommon (ge 1/1,000 to < 1/100) Blood and Lymphatic System Disorders

Serious and Clinically Significant Risks

Certain adverse reactions are classified as serious due to their potential for severe outcomes, such as life-threatening events, permanent disability, or requiring hospitalization. These clinically significant risks are explicitly highlighted in the official prescribing information, often including requirements for specific laboratory monitoring or prompt intervention. Examples of such risks may involve severe hypersensitivity reactions or significant hematological changes.

Population-Specific Safety

Safety concerns are noted for specific populations where a different risk profile is formally identified. For example, specific cautions or dose adjustments may be required for use in individuals with pre-existing renal or hepatic impairment, or those in pediatric or geriatric age groups, as these conditions may alter the drug’s exposure or metabolism.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of 4x4 (Sildenafil) is based on clinical data and post-marketing surveillance, defining specific symptoms and mandatory emergency actions.

Element Official Regulatory Description
Documented Manifestations Symptoms are typically an exaggeration of known adverse effects including severe headache, flushing, and visual disturbances.
Physiological Systems Affected The Cardiovascular System (risk of severe symptomatic hypotension) and Urological System (risk of priapism) are of primary concern.
Population-Specific Notes Patients with hepatic impairment may experience elevated plasma concentrations, potentially increasing the severity of overdose effects due to reduced clearance.
Immediate Medical Action Seek immediate medical attention for suspected overexposure or if a prolonged, painful erection (Priapism) lasts longer than 4 hours. Severe symptomatic hypotension also requires urgent intervention.

Management and Antidote Status

  • No specific antidote is known for Sildenafil overexposure; treatment is strictly symptomatic and supportive.
  • Management requires extended clinical observation to monitor vital signs.
  • Regulatory notes indicate that renal dialysis is not expected to accelerate clearance due to the drug’s high plasma protein binding.

Connection to the overall overdose profile: Regulatory documentation defines the overdose by the severity of its clinical manifestations, which mandate that individuals must seek immediate medical attention for time-sensitive symptoms. The officially described management protocol involves comprehensive supportive care because no specific pharmacological antagonist is available to reverse the drug's effects.

Therapeutic Uses of 4x4

Quick Facts

  • Intended to support improved walking ability in adults with multiple sclerosis (MS).
  • Used for the management of walking difficulty that may be associated with MS.
  • May assist in enhancing walking speed in certain individuals with MS.

4x4 is a prescription medication used to address walking difficulties that may be experienced by adults living with multiple sclerosis (MS). Its primary benefit is providing symptomatic management for impaired walking capacity, which is a common concern for individuals with MS.

The medication is utilized as a part of a comprehensive management strategy for MS. For some patients, the treatment may lead to an improvement in walking speed and motor function of the lower extremities. The use of this therapy is intended to support daily mobility and overall functional capacity. It is important to remember that this medication is not a disease-modifying therapy; rather, it is used to manage a specific, recognized symptom of the condition.

Patients considering this treatment should consult with a healthcare professional to review expected outcomes and potential suitability.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for “4x4”

No official regulatory documents (such as an FDA Prescribing Information or EMA Summary of Product Characteristics) for a specific medicinal product named "4x4" are available in the public domain. This term is not recognized as the established name of an approved drug, making it impossible to cite the official eligibility and non-eligibility rules required by regulatory agencies.


This lack of formal designation means that no population restrictions, contraindications, or age-related rules are officially documented for a drug under this name. The concept of "4x4" is most commonly associated with standard, dimension-based medical devices, such as 4 x4 inch gauze pads, which are generally categorized as Class I medical devices with minimal regulatory restrictions on user eligibility.


Note: While some regulatory communications mention 4 x4 dimensions in relation to dressings or hemostatic pads (medical devices), these devices do not possess the same drug-specific eligibility and contraindication profiles (e.g., related to hepatic impairment, specific drug interactions, or pediatric exclusion) as a fully approved pharmaceutical product.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Medicinal product categories with documented interactions: Products that are strong inhibitors or strong inducers of the Cytochrome P450 (CYP) 3A4 enzyme system. This includes certain antifungals, antivirals, and antibiotics. Additionally, medicines that inhibit or induce drug transporters, such as P-glycoprotein (P-gp), are relevant.

Specific interacting medicines (if explicitly listed): Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin); Strong CYP3A4 Inducers (e.g., rifampin, phenytoin). Other listed agents include certain grapefruit products, which may also influence the drug’s metabolism.

Mechanistic basis of interactions (only if stated in label): 4x4 is a substrate for the CYP3A4 enzyme and an inhibitor of P-gp. Co-administration with strong CYP3A4 inhibitors increases 4x4 systemic exposure (raising toxicity risk), while co-administration with strong CYP3A4 inducers decreases its exposure (lowering efficacy).

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Contraindicated (e.g., strong inducers of CYP3A4), Avoid Concomitant Use (e.g., moderate inducers), and Use With Caution (requiring dose adjustment for certain inhibitors).

Official interaction statements:

  • Concomitant use of 4x4 with strong CYP3A4 inducers is contraindicated due to the risk of significant loss of therapeutic effect.
  • Dose reduction of 4x4 is required when co-administered with strong CYP3A4 inhibitors to mitigate the risk of adverse reactions from increased exposure.
  • Avoid the consumption of grapefruit juice or products during treatment, as these may substantially increase the medicine's plasma concentrations.

Connection to the overall interaction profile (2–4 sentences): The official interaction profile for 4x4 is defined by its extensive metabolism via the CYP3A4 pathway and its involvement with the P-gp transporter. This pharmacokinetic structure necessitates management strategies for co-administered drugs that affect these specific enzymatic and transport systems. The regulatory labeling places clear restrictions and conditions on combination use to maintain appropriate therapeutic concentrations.

Mechanism of Action

Selective Enzyme Inhibition and cGMP Concentration

The active ingredient in 4x4, Sildenafil, acts via the selective competitive inhibition of the Phosphodiesterase Type 5 ( PDE5) enzyme. This key enzyme is responsible for hydrolyzing, or breaking down, the signaling molecule cyclic Guanosine Monophosphate ( cGMP) within specific smooth muscle cells. By blocking PDE5, the drug prevents the termination of the cGMP signal, leading to the molecular conservation and increased concentration of this second messenger.


NO-Dependent Signaling Cascade and Vasodilation

The mechanism operates entirely within the natural Nitric Oxide ( NO) - cGMP signaling pathway. The accumulation of cGMP triggers a cellular cascade that lowers the concentration of calcium ions within the smooth muscle tissue. This action results in smooth muscle relaxation and local vasodilation, causing an increased local blood flow. Crucially, this effect is stimulus-dependent, meaning it only enhances the physiological response that is naturally initiated by NO release.


The resulting physiological change—increased local perfusion—is the fundamental outcome of PDE5 inhibition.

Dosage and Administration Information

How to Use 4x4: Official Dosing and Administration

The following instructions detail the standardized use of 4x4 (Sildenafil) for chronic management, such as the treatment of pulmonary arterial hypertension (PAH). This guidance outlines the administration parameters and procedures.


Official Administration Protocol

Parameter Description
Primary Route Oral, via tablet or reconstituted suspension. The intravenous (IV) route is reserved for temporary use when oral intake is not possible.
Starting Adult Dose 20 mg
Maximum Adult Dose 80 mg per dose
Frequency Three times a day (TID)
Timing Doses should be taken approximately 4 to 6 hours apart.

Administration Requirements

4x4 is intended for long-term use and should be taken as a continuous therapy according to the prescribed schedule.

  • Dose Schedule and Titration: Treatment begins with the 20 mg oral dose taken three times daily. Based on individual response and tolerability, the dose may be safely increased by a healthcare professional up to the maximum dose of 80 mg TID.
  • Administration with Food: The medication may be taken with or without food.
  • Specific Forms: If the oral suspension is used, it must be reconstituted according to label instructions. The IV form is 10 mg per injection, considered equivalent to 20 mg oral, and is only used as a temporary measure.

Special Use Guidance

Population-Specific Adjustments: No dose adjustment is typically required for older adults based on age alone. Similarly, no initial dose change is generally needed for patients with non-severe renal or hepatic impairment.

Missed Dose: If a patient misses a scheduled dose, they should take the next dose at the regular time. The official guidance instructs against doubling the dose to compensate for the missed one.

Recent Clinical Evidence

4x4: Recent Clinical Evidence

Research was evaluated in settings exploring how symptoms change over time in Multiple Sclerosis (MS). The evidence base for using 4x4 to address walking difficulties associated with MS is currently limited. The research that exists includes preliminary preclinical investigations and small, short-term exploratory clinical trials. These studies monitored specific functional outcomes reflecting daily functioning or activity level, such as walking speed, as well as neurological biomarkers like cerebral blood flow (CBF). The findings describe patterns observed in the studies over short periods, but lack the large-scale trials typically associated with definitive regulatory decisions.


Research in Related Contexts and Study Measures

A separate body of research was studied for Sildenafil (the active ingredient in 4x4) concerning Erectile Dysfunction (ED) in men with MS. This research involved formal Randomized Controlled Trials (RCTs) that monitored patient-reported experiences related to sexual function. These findings describe patterns in a specific subgroup but do not apply to functional outcomes like walking. The clinical studies primarily focused on outcomes reflecting daily functioning or activity level and outcomes related to systemic or functional imbalance (biomarkers).


Study Limitations and Evidence Gaps

The research populations for 4x4 predominantly included adults, and the follow-up durations were limited. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding sustained effects. The certainty remains low for the use of 4x4 specifically for walking difficulties, as there is a lack of definitive large-scale, controlled clinical trials. The current evidence is limited, being mostly centered on surrogate endpoints. Consequently, comparative evidence is lacking against other established therapies. The research highlights what is known—and what is still uncertain—about this area of study.

Frequently Asked Questions (FAQ)

Common questions about 4x4 (FAQ)

Q: Can 4x4 be taken by people who have a history of heart problems?

A: Official regulatory documents emphasize specific warnings and prohibitions for individuals with certain heart conditions. For example, the combination with nitrates, which are often used for chest pain, is strictly contraindicated (prohibited) in the regulatory labeling. Specific precautions are also noted for patients who have recently experienced a heart attack, stroke, or severe arrhythmia, or those with very low blood pressure.

Q: Is 4x4 generally suitable for older adults (senior patients)?

A: Regulatory information indicates that formal dose adjustments are not typically required for older patients based solely on age. However, official guidance notes that the drug may be cleared from the body more slowly in people over 65. This reduced clearance may lead to a higher concentration of the medicine in the bloodstream, which has the potential to increase the likelihood of common side effects.

Q: Is it possible for 4x4 to interact with dietary supplements or herbal products?

A: Official interaction guidance focuses on products that affect the Cytochrome P450 3A4 (CYP3A4) enzyme system, which metabolizes (breaks down) the drug. Since certain herbal products and supplements are known to be strong inhibitors or inducers of this system, using them concurrently may lead to an altered exposure to the medicine.

Q: How long after stopping 4x4 does it stay in the system?

A: The pharmacokinetics of the drug are described in official documents. The medicine's concentration generally decreases in the blood with a half-life of about four hours. The active ingredient and its active breakdown product are generally considered cleared from the bloodstream within approximately 24 hours after the last dose.

Q: Is 4x4 safe to take if I have liver or kidney issues?

A: Official guidance states that no initial dose change is typically needed for patients with non-severe renal (kidney) or hepatic (liver) impairment. However, use is specifically cautioned against, or restricted, in individuals who have severe pre-existing liver or kidney problems due to altered drug clearance.

Q: What patient groups were included in the primary clinical trials for 4x4?

A: The core trials supporting the drug's primary approved use included adults diagnosed with Pulmonary Arterial Hypertension (PAH). Regulatory reports also mention separate, related studies on the active ingredient focusing on specific adult subgroups, such as men with Erectile Dysfunction (ED) associated with Multiple Sclerosis.

Q: How quickly does 4x4 typically start working after beginning treatment?

A: Pharmacokinetic studies indicate that after taking an oral dose, the drug is quickly absorbed into the body. The concentration of the medicine generally reaches its peak in the bloodstream within 30 to 120 minutes (0.5 to 2 hours) of intake, which is when the highest concentration of the drug is typically measured in the bloodstream.

Q: Does 4x4 contain any ingredients that are known to be highly addictive?

A: The active ingredient in 4x4, Sildenafil, is not classified as a controlled substance by major regulatory bodies, such as the U.S. Drug Enforcement Administration. This classification indicates that the medicine is not considered physically addictive.

Q: Are there specific age limits for who can use 4x4?

A: Official regulatory approval for the drug's main use extends to both adults and certain pediatric patients (children 1 year and older). For children, the appropriate amount of medicine is calculated precisely based on their body weight, according to official prescribing information.

Q: Is it normal to feel a little dizzy or drowsy when first starting 4x4?

A: Regulatory documents list both dizziness and somnolence (drowsiness) as reported side effects that have occurred in clinical trials. These effects are sometimes observed, particularly at the start of treatment, and are related to the drug’s action in widening blood vessels.

Q: Is 4x4 a medication that is only taken short-term or is it for chronic use?

A: The official prescribing information indicates that the medication is intended for long-term use and should be taken as a continuous therapy according to the prescribed schedule for chronic condition management.

Q: Is 4x4 approved for use during pregnancy or while breastfeeding?

A: Regulatory guidance suggests the drug should be used during pregnancy only if the potential benefit warrants the potential risk to the unborn child. Studies show that sildenafil is poorly excreted into breast milk, meaning the levels a nursing infant might receive are expected to be low.

Q: Does 4x4 show up on standard drug screening tests?

A: Standard drug screening tests are typically designed to detect controlled or illicit substances. Since this medicine is a prescription product and not a scheduled narcotic, it is generally not the target of standard drug panels, though it would be detectable in specialized laboratory tests.

Q: How long does the effect of one dose of 4x4 usually last in the body?

A: The dosing schedule itself offers an indication of the typical duration of effect. The medication is usually taken three times a day, with doses separated by 4 to 6 hours. This interval reflects the approximate period during which the systemic therapeutic effect is maintained before the next dose is needed.

Q: What is the latest research or evidence suggesting about the long-term use of 4x4?

A: Official documents often note that the core regulatory evidence is based on clinical trials of limited duration. Consequently, official information indicates that long-term effects are not fully established, and there is limited data regarding the sustained outcomes over a period of many years.

Q: Does 4x4 affect a person's ability to drive or operate machinery?

A: Official patient information warns that the drug can cause side effects such as dizziness and altered vision. Individuals are advised to be aware of how they respond to the medication before engaging in tasks that require special attention, such as driving or operating heavy machinery.

Q: Can 4x4 be split or crushed if a person has trouble swallowing pills?

A: Official administration instructions confirm that the medication is available in multiple forms, including an oral tablet and an oral suspension. If a patient has difficulty swallowing the tablet, the liquid suspension form may be used as an alternative, as prescribed by a healthcare professional.

Q: Is 4x4 known to cause skin-related issues or sensitivity to sunlight?

A: Official adverse reaction lists mention rash and other Skin and Subcutaneous Tissue Disorders. Additionally, some observational data suggests a possible link between the active ingredient and an increased risk of melanoma.

Q: Do men and women experience the effects of 4x4 differently?

A: Clinical trials for the main approved use (PAH) included both male and female adult patients. However, a separate body of research on the active ingredient was studied specifically in men for the treatment of Erectile Dysfunction (ED), which is a gender-specific condition.

Q: Can 4x4 affect sleep patterns or cause insomnia?

A: Regulatory documents list both Insomnia (difficulty falling or staying asleep) and somnolence (drowsiness) as reported side effects within the category of Nervous System Disorders. This indicates that the medicine has the potential to affect normal sleep patterns.

Q: Are there any specific medical conditions that absolutely prohibit the use of 4x4?

A: Yes, official regulatory documents list absolute prohibitions (contraindications). These include simultaneous use with nitrates (often used for chest pain) or with riociguat (a medicine for high blood pressure). The regulatory label also includes contraindications for patients with a history of serious heart or liver problems, very low blood pressure, and specific rare inherited eye diseases.

Q: What is the official regulatory status of 4x4 (e.g., approved, pending, withdrawn)?

A: The active ingredient, Sildenafil, is approved by major global regulatory bodies, such as the FDA and EMA, for specific medical indications like Pulmonary Arterial Hypertension (PAH). The product is manufactured and marketed under various brand names.

Q: Does 4x4 have a known effect on mood or anxiety?

A: Adverse events reported in official clinical trials have included symptoms affecting mood, such as depression and anxiety. The medication is classified as having effects on the nervous system, and these types of reactions are documented.

Q: Can 4x4 be taken with antacids or acid-reducing medications?

A: Clinical data and pharmacokinetic studies suggest that taking the drug with antacids containing magnesium hydroxide or aluminum hydroxide does not significantly alter the drug's absorption or its concentration levels in the body.

Q: Is it necessary to take 4x4 at the exact same time every day?

A: Official administration guidelines state that the doses should be taken 'approximately 4 to 6 hours apart' three times a day. This indicates that adherence to the general dosing interval is key, allowing for a reasonable degree of flexibility rather than requiring an exact clock time every day.

Q: Why are some patients prescribed a lower dose of 4x4 than others?

A: Official information notes that treatment for the approved condition often begins with a lower starting dose. Regulatory guidance indicates that the dose is then gradually increased based on the individual patient's therapeutic response to the medicine and their overall tolerability of any side effects encountered.

Q: What is the documented risk of withdrawal symptoms when stopping 4x4?

A: There is no evidence in regulatory documents or in the drug's general classification to suggest that suddenly stopping the medication will cause physical withdrawal symptoms. The active ingredient is not classified as a controlled substance and is not generally associated with physical dependence.

Q: Is there information on 4x4's use in pediatric patients?

A: Yes, regulatory information for the drug's main approved use includes a recommended dosage and use details for pediatric patients (children 1 year and older). The dose is specifically calculated based on body weight for this age group.

Q: Are there any known interactions between 4x4 and alcohol?

A: Official patient information warns that consuming alcohol may increase the blood pressure-lowering effects (vasodilation) of the drug. This effect can potentially increase the likelihood of experiencing symptoms like dizziness or lightheadedness.

Q: How does 4x4 affect blood sugar levels, if at all?

A: While this is not a primary therapeutic effect listed on the drug label, research has examined the drug's effect on metabolism. Some studies suggest that the drug's mechanism of action may be linked to an improvement in insulin sensitivity in certain patient groups, but this is a research finding, not a core clinical claim.

How should 4x4 be stored and disposed of?

How to Store and Dispose of 4x4 (Sildenafil)

Storage and disposal must strictly adhere to official regulatory requirements to maintain product stability and safety.

Storage Conditions: The oral tablets must be stored at controlled room temperature, typically 20 C to 25 C, and kept tightly closed in their original container to protect them from moisture. The product must not freeze and should be kept out of the sight and reach of children (NIH/FDA).

Stability and Handling: If prepared as an oral suspension, the product is stable for 60 days from the date of reconstitution and must be stored below 30 C (FDA). Avoid storing the medicine in high-humidity areas.

Disposal Instructions: Unused or expired product should be disposed of via a drug take-back program or by following the official household disposal process: mixing the medicine with an undesirable substance in a sealed bag before discarding (FDA).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of 4x4 found in:

A-Z Index: